{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:52Z","timestamp":1794925552045,"version":"4.9.1"},"reference-count":66,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy. The recent availability of new pharmacologic therapies presents a valuable opportunity to reevaluate how this disease is classified, assessed, and managed and identify new ways to improve the clinical care of patients with gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Narrative review was made of publications identified via searches of PubMed and selected congresses (January 2000\u2013September 2022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>New consensus definitions are required to ensure consistency, to better characterize patients, and to identify patients who will benefit from specific drugs and earlier use of these agents. There is a need for more frequent, standardized patient assessment to identify the cause of motor function deficits, provide a clearer picture of the disease burden and its impact on daily living and quality of life (QoL), and better support treatment decision\u2010making. Novel approaches that target different components of the immune system will play a role in more precise treatment of patients with gMG, alongside the development of new algorithms to guide individualized patient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence key pathological mediators of gMG, together with new biomarkers, offers the potential to optimize patient management and ultimately enables a greater number of patients to achieve minimal manifestation status and a reduced burden of disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.16180","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:36:15Z","timestamp":1703072175000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-6317","authenticated-orcid":false,"given":"Francesco","family":"Sacc\u00e0","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort\u2010Campana","sequence":"additional","affiliation":[{"name":"Reference Center of Neuromuscular Disorders and ALS, Timone University Hospital Assistance Publique\u2013Hopitaux de Marseille  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy University of Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-1072","authenticated-orcid":false,"given":"Elena","family":"Cort\u00e9s\u2010Vicente","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit, Department of Neurology Hospital de la Santa Creu i Sant Pau and Biomedical Research Institute Sant Pau  Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9232-201X","authenticated-orcid":false,"given":"Christiane","family":"Schneider\u2010Gold","sequence":"additional","affiliation":[{"name":"Department of Neurology St. Josef Hospital of Ruhr\u2010University Bochum  Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard A","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.17925\/ENR.2018.13.1.18"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00707"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2017.253"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816666206"},{"issue":"263","key":"e_1_2_9_12_1","first-page":"235","article-title":"Possible evidence for a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients","volume":"70","author":"Hawkins BR","year":"1989","journal-title":"Q J Med"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.37.12.1854"},{"issue":"2","key":"e_1_2_9_14_1","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh J","year":"2013","journal-title":"Yale J Biol Med"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00981"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01860-y"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.1952982"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14391"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000202"},{"key":"e_1_2_9_31_1","unstructured":"CaetanoJ BatistaF DelgadoAJ.Hypogammaglobulinemia and infection risk in patients treated with rituximab [abstract].2022.https:\/\/acrabstracts.org\/abstract\/hypogammaglobulinemia\u2010and\u2010infection\u2010risk\u2010in\u2010patients\u2010treated\u2010with\u2010rituximab."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"issue":"23","key":"e_1_2_9_37_1","first-page":"S37","article-title":"Long\u2010term safety and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study","volume":"99","author":"Howard JF","year":"2022","journal-title":"Neurology"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_2_9_39_1","unstructured":"BrilV DruzdzA GrosskreutzJ et\u00a0al.Efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis: a randomized multicenter double\u2010blind placebo\u2010controlled phase 3 study (MycarinG). Presented at: 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia Gravis and Related Disorders Miami FL USA.2022."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S266031"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211065406"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_2_9_44_1","unstructured":"HowardJFJr UtsugisawaK BenatarM et\u00a0al.Outcomes from RAISE: a randomized placebo\u2010controlled double\u2010blind phase 3 trial of zilucoplan in generalized myasthenia gravis. Presented at: 14th Myasthenia Gravis Foundation of America (MGFA) International Conference Miami FL USA.2022."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01380-2"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14124"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012604"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10902-1"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00285-w"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506310"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010574"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000858"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2184257"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00463-4"},{"key":"e_1_2_9_63_1","volume-title":"IfCaE. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value final report","author":"Review","year":"2021"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100111"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00213"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-019-1571-9"},{"key":"e_1_2_9_67_1","first-page":"1360","article-title":"Complement activation profile in myasthenia gravis patients: perspectives for tailoring anti\u2010complement therapy","volume":"10","author":"Iacomino N","year":"2022","journal-title":"Biomedicine"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T06:21:47Z","timestamp":1715149307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ene.16180"],"URL":"https:\/\/doi.org\/10.1111\/ene.16180","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"2023-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16180"}}